{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:37:28Z","timestamp":1786599448522,"version":"build-2736575974"},"reference-count":44,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,2,5]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The similarity in retention of tumour necrosis factor inhibitors (TNFi) and tofacitinib (TOFA) was previously reported separately by the Ontario Best Practices Research Initiative and the Quebec cohort Rhumadata. However, because of small sample sizes in each registry, we aimed to confirm the findings by repeating the analysis of discontinuation of TNFi compared with TOFA, using pooled data from both these registries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Pooled data from two rheumatoid arthritis (RA) registries in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with RA starting TOFA or TNFi between June 2014 and December 2019 were included. A total of 1318 patients were included TNFi (n=825) or TOFA (n=493).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Time to discontinuation was assessed using Kaplan-Meier survival and Cox proportional hazards regression analysis. Propensity score (PS) stratification (deciles) and PS weighting were used to estimate treatment effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean disease duration in the TNFi group was shorter (8.9 years vs 13 years, p&lt;0.001). Prior biological use (33.9% vs 66.9%, p&lt;0.001) and clinical disease activity index (20.0 vs 22.1, p=0.02) were lower in the TNFi group.<\/jats:p>\n                    <jats:p>Discontinuation was reported in 309 (37.5%) and 181 (36.7%) TNFi and TOFA patients, respectively. After covariate adjustment using PS, there was no statistically significant difference between the two groups in discontinuation due to any reason HR=0.96 (95% CI 0.78 to 1.19, p=0.74)) as well as discontinuation due to ineffectiveness only HR=1.08 (95% CI 0.81 to 1.43, p=0.61)).<\/jats:p>\n                    <jats:p>TNFi users were less likely to discontinue due to adverse events (AEs) (adjusted HRs: 0.46, 95%\u2009CI 0.29 to 0.74; p=0.001). Results remained consistent for firstline users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this pooled real-world data study, the discontinuation rates overall were similar. However, discontinuation due to AEs was higher in TOFA compared with TNFi users.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063198","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T10:45:26Z","timestamp":1678272326000},"page":"e063198","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-0121","authenticated-orcid":false,"given":"Mohammad","family":"Movahedi","sequence":"first","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"IHMPE, Univeristy of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Choquette","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institut de Rhumatologie de Montr\u00e9al, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Coupal","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institut de Rhumatologie de Montr\u00e9al, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cesta","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuying","family":"Li","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C","family":"Keystone","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"IHMPE, Univeristy of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"OBRI","family":"Investigators","sequence":"additional","affiliation":[{"name":"Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"2025121601515999000_13.3.e063198.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2025121601515999000_13.3.e063198.2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.38306","article-title":"The epidemiology of rheumatoid arthritis in Ontario, Canada","volume":"66","author":"Widdifield","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025121601515999000_13.3.e063198.3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025121601515999000_13.3.e063198.4","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025121601515999000_13.3.e063198.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025121601515999000_13.3.e063198.6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121601515999000_13.3.e063198.7","first-page":"485","article-title":"Real-World experience with tofacitinib for the treatment of rheumatoid arthritis","volume":"37","author":"Caporali","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025121601515999000_13.3.e063198.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025121601515999000_13.3.e063198.9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40744-019-00177-4","article-title":"Real-World comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis","volume":"6","author":"Reed","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025121601515999000_13.3.e063198.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177057","article-title":"Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis","volume":"12","author":"Iwamoto","year":"2017","journal-title":"PLoS One"},{"key":"2025121601515999000_13.3.e063198.11","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025121601515999000_13.3.e063198.12","first-page":"1457","article-title":"Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database","volume":"22","author":"Harnett","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2025121601515999000_13.3.e063198.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"2025121601515999000_13.3.e063198.14","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic dmards in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025121601515999000_13.3.e063198.15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s10067-020-05021-7","article-title":"Real-World evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia","volume":"39","author":"Bird","year":"2020","journal-title":"Clin Rheumatol"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.16.1","doi-asserted-by":"crossref","unstructured":"Choquette D , Bessette L , Sauvageau LC , et al . SAT0120\u2005COMPARATIVE effectiveness of tofacitinib and TNF inhibitors since 2014. impact of combination with methotrexate. Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12-15 June 2019","DOI":"10.1136\/annrheumdis-2019-eular.3110"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.16.2","doi-asserted-by":"crossref","unstructured":"June 2019 doi:10.1136\/annrheumdis-2019-eular.3110","DOI":"10.1136\/annrheumdis-2019-eular.3110"},{"key":"2025121601515999000_13.3.e063198.17","doi-asserted-by":"crossref","unstructured":"Movahedi M , Cesta A , Li X , et al . Discontinuation rate of tofacitinib is similar when compared to TNF inhibitors in rheumatoid arthritis patients: real world results from a rheumatoid arthritis cohort. ACR 2020. doi:10.1136\/annrheumdis-2020-eular.1745","DOI":"10.1136\/annrheumdis-2020-eular.1745"},{"key":"2025121601515999000_13.3.e063198.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180486"},{"key":"2025121601515999000_13.3.e063198.19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.semarthrit.2020.06.020","article-title":"Discontinuation of biologic therapy due to lack\/loss of response and adverse events is similar between tnfi and non-tnfi class: results from a real-world rheumatoid arthritis cohort","volume":"50","author":"Movahedi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025121601515999000_13.3.e063198.20","doi-asserted-by":"crossref","unstructured":"Rubin DB . Multiple imputation for nonresponse in surveys. In: Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ, USA: John Wiley & Sons, 9 June 1987. doi:10.1002\/9780470316696","DOI":"10.1002\/9780470316696"},{"key":"2025121601515999000_13.3.e063198.21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","article-title":"Multiple imputation of missing blood pressure covariates in survival analysis","volume":"18","author":"van Buuren","year":"1999","journal-title":"Statist Med"},{"key":"2025121601515999000_13.3.e063198.22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"2025121601515999000_13.3.e063198.23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"2025121601515999000_13.3.e063198.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0253-9","article-title":"Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma","volume":"16","author":"Pezzi","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2025121601515999000_13.3.e063198.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"2025121601515999000_13.3.e063198.26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8355"},{"key":"2025121601515999000_13.3.e063198.27","unstructured":"Meyers JP . The %newsurv family of macros: an update on the survival plotting macro %newsurv and an introduction to expansion macros. Proceeding of Pharmaceutical SAS Users Group Conference (PharmaSUG 2017) Paper DV15; Carry, NC: SAS Institute Inc, 2017"},{"key":"2025121601515999000_13.3.e063198.28","unstructured":"Haynes RB . A critical review of the \u201cdeterminants\u201d of patient compliance with therapeutic regimens. Baltimore, MD: Johns Hopkins University Press, 1976."},{"key":"2025121601515999000_13.3.e063198.29","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/rheumatology\/kez671","article-title":"Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? an analysis of the British Society for rheumatology biologics register","volume":"59","author":"Bechman","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025121601515999000_13.3.e063198.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.31.1","doi-asserted-by":"crossref","unstructured":"Mimori T , Harigai M , Atsumi T , et al . AB0431\u2005Post-marketing surveillance of tofacitinib in japanese patients with rheumatoid arthritis: an interim report of safety data. Annual European Congress of Rheumatology, 14-17 June, 2017","DOI":"10.1136\/annrheumdis-2017-eular.1420"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.31.2","doi-asserted-by":"crossref","unstructured":"June 2017:1200 doi:10.1136\/annrheumdis-2017-eular.1420","DOI":"10.1136\/annrheumdis-2017-eular.1420"},{"key":"2025121601515999000_13.3.e063198.32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","article-title":"Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-na\u00efve and experienced patients","volume":"57","author":"Mori","year":"2018","journal-title":"Intern Med"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.33.1","doi-asserted-by":"crossref","unstructured":"Sansinanea P , Costi AC , Vulcano A , et al . AB0434\u2005Tofacitinib in rheumatoid arthritis: real life experience. Annual European Congress of Rheumatology, 14-17 June, 2017","DOI":"10.1136\/annrheumdis-2017-eular.3861"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.33.2","doi-asserted-by":"crossref","unstructured":"June 2017:1202 doi:10.1136\/annrheumdis-2017-eular.3861","DOI":"10.1136\/annrheumdis-2017-eular.3861"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.34.1","doi-asserted-by":"crossref","unstructured":"Schneeberger E , Salas A , Medina L , et al . AB0419\u2005Real world use of tofacitinib in rheumatoid arthritis: data from latin america. Abstract. Annual European Congress of Rheumatology, 14-17 June, 2017","DOI":"10.1136\/annrheumdis-2017-eular.1607"},{"key":"#cr-split#-2025121601515999000_13.3.e063198.34.2","doi-asserted-by":"crossref","unstructured":"June 2017 doi:10.1136\/annrheumdis-2017-eular.1607","DOI":"10.1136\/annrheumdis-2017-eular.1607"},{"key":"2025121601515999000_13.3.e063198.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219699"},{"key":"2025121601515999000_13.3.e063198.36","doi-asserted-by":"crossref","unstructured":"Mueller R , Popp F , Mattow F , et al . AB0497\u2005Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: A retrospective analysis of real-world data from the st. gallen and aarau cohort. Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13\u201316 June 2018 2018:69. doi:10.1136\/annrheumdis-2018-eular.5524","DOI":"10.1136\/annrheumdis-2018-eular.5524"},{"key":"2025121601515999000_13.3.e063198.37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/acr2.1010","article-title":"Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 9.5 years","volume":"1","author":"Pope","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2025121601515999000_13.3.e063198.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139774"},{"key":"2025121601515999000_13.3.e063198.39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.46497\/ArchRheumatol.2020.7499","article-title":"Factors predicting early failure of etanercept in rheumatoid arthritis: an analysis from the Gruppo Italiano di Studio sulla early arthritis (Italian group for the study of early arthritis) registry","volume":"35","author":"Sebastiani","year":"2020","journal-title":"Arch Rheumatol"},{"key":"2025121601515999000_13.3.e063198.40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:52:14Z","timestamp":1765878734000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,6]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjopen-2022-063198"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063198","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}